CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of immunotherapy nivolumab and the
targeted therapy cabozantinib prior to removal of the kidney, will increase the number
subjects who are without any visible kidney cancer in their body at some point during the
course of treatment.